Compare ResMed Inc. (RMD) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Ross Stores, Inc. — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Ross Stores, Inc. trades at $225 (market cap $73.25B). The key difference: Ross Stores, Inc. is far larger — about 2.3× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| RMD | ROST | |
|---|---|---|
Market Cap | $31.89B | $73.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $283.28 | $255.23 |
52-Week Low | $182.82 | $144.67 |
Enterprise Value | $31.24B | $73.70B |
Dividend Yield | 1.19% | 0.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Ross Stores (ROST) trades at $229.31, down 0.6% on the day, showing bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.66 beating expectations by 36%. Revenue growth accelerated to 13% in Q2 2026, with comparable store sales surging 10% driven by increased traffic and margin expansion. The stock faces technical resistance near $234 while maintaining strong analyst support with a $271.33 consensus price target.
ROST presents a compelling growth story with robust fundamentals but faces near-term technical headwinds. The company's value-focused retail strategy resonates with cost-conscious consumers, driving consistent earnings outperformance. Key risks include competitive pressures in off-price retail and macroeconomic sensitivity. With 64% of analysts maintaining buy ratings and a 19% upside to consensus targets, the stock offers growth potential for investors comfortable with current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
